-- Successfully commenced U.S. commercial launch of LUMRYZ™-- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 -- -- Significant early progress on payor coverage, prescriber certifications and patient enrollments -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform

Related Keywords

United States , Dublin , Ireland , American , Courtney Turiano , Greg Divis , Lesley Stanley , Avadel Pharmaceuticals , Securities Exchange , Stern Investor Relations Inc , Us Food Drug Administration , Company Annual Report On Form , Young Investigators Research Forum , American Academy Of Sleep Medicine , Nasdaq , Exchange Commission , Research Society , National Preferred Formulary , Academy Of Sleep Medicine Foundation , Chief Executive Officer , Recent Company , Express Scripts , Orphan Drug , American Academy , Sleep Medicine , Sleep Research , Sleep Medicine Foundation , Investigators Research , Once Nightly Sodium Oxybate , Narcolepsy Type , Post Hoc Analysis From , Second Quarter , American Depositary Shares , Orphan Drug Exclusivity , Drug Administration , Prescribing Information , Securities Act , Securities Exchange Act , Annual Report , Investor Relations , Months Ended June , Fda Approval , Narcolepsy , Sodium Oxybate , The Company , Company , Umryz , Fda ,